Chemistry:LY-2183240
| |
| Names | |
|---|---|
| IUPAC name
N,N-dimethyl-5-[(4-biphenyl)methyl]tetrazole-1-carboxamide
| |
| Identifiers | |
3D model (JSmol)
|
|
| ChemSpider | |
PubChem CID
|
|
| UNII | |
| |
| |
| Properties | |
| C17H17N5O | |
| Molar mass | 307.349 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
| Infobox references | |
LY-2183240 is a drug which acts both as a potent inhibitor of the reuptake of the endocannabinoid anandamide and as an inhibitor of fatty acid amide hydrolase (FAAH), the primary enzyme responsible for degrading anandamide. This leads to markedly elevated anandamide levels in the brain, and LY-2183240 has been shown to produce both analgesic and anxiolytic effects in animal models.[1][2][3] While LY-2183240 is a potent inhibitor of FAAH, it has relatively poor selectivity and also inhibits several other enzyme side targets.[4] Consequently, it was never developed for clinical use, though it remains widely used in research, and has also been sold as a designer drug.[5]
See also
- Endocannabinoid reuptake inhibitor
- FAAH inhibitor
- BIA 10-2474
- PF-04457845
- URB-597
References
- ↑ Dickason-Chesterfield AK, Kidd SR, Moore SA, Schaus JM, Liu B, Nomikos GG, Felder CC (2006). "Pharmacological characterization of endocannabinoid transport and fatty acid amide hydrolase inhibitors". Cellular and Molecular Neurobiology 26 (4–6): 407–23. doi:10.1007/s10571-006-9072-6. PMID 16736384.
- ↑ Maione S, Morera E, Marabese I, Ligresti A, Luongo L, Ortar G, Di Marzo V (Nov 2008). "Antinociceptive effects of tetrazole inhibitors of endocannabinoid inactivation: cannabinoid and non-cannabinoid receptor-mediated mechanisms". British Journal of Pharmacology 155 (5): 775–82. doi:10.1038/bjp.2008.308. PMID 18660824.
- ↑ Powers MS, Barrenha GD, Mlinac NS, Barker EL, Chester JA (Dec 2010). "Effects of the novel endocannabinoid uptake inhibitor, LY2183240, on fear-potentiated startle and alcohol-seeking behaviors in mice selectively bred for high alcohol preference". Psychopharmacology 212 (4): 571–83. doi:10.1007/s00213-010-1997-2. PMID 20838777.
- ↑ Alexander JP, Cravatt BF (Aug 2006). "The putative endocannabinoid transport blocker LY2183240 is a potent inhibitor of FAAH and several other brain serine hydrolases". Journal of the American Chemical Society 128 (30): 9699–704. doi:10.1021/ja062999h. PMID 16866524.
- ↑ Uchiyama N, Matsuda S, Kawamura M, Shimokawa Y, Kikura-Hanajiri R, Aritake K, Urade Y, Goda Y (2014). "Characterization of four new designer drugs, 5-chloro-NNEI, NNEI indazole analog, α-PHPP and α-POP, with 11 newly distributed designer drugs in illegal products". Forensic Sci Int 243: 1–13. doi:10.1016/j.forsciint.2014.03.013. PMID 24769262.
Further reading
Moore, S. A.; Nomikos, G. G.; Dickason-Chesterfield, A. K.; Schober, D. A.; Schaus, J. M.; Ying, B. P.; Xu, Y. C.; Phebus, L et al. (2005). "Identification of a high-affinity binding site involved in the transport of endocannabinoids". Proceedings of the National Academy of Sciences 102 (49): 17852–7. doi:10.1073/pnas.0507470102. PMID 16314570.
 |  |
